SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

SCYNEXIS, Inc. (SCYX) News

Follow SCYNEXIS, Inc. (SCYX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol SCYX Asset equity Sector Markets 90 days 20 Last 2.365 Updated Nov 05, 2026, 03:33 PM UTC Open live news feed Open SCYX chart & news
M SCYNEXIS Reports Quarterly Results for Quarter Ended September 30 EQUITY | Nov 05, 2026, 03:33 PM UTC M Scynexis Posts Q3 Net Loss on Higher R&D Costs EQUITY | Nov 05, 2026, 01:33 PM UTC M Scynexis Reports Third-Quarter Revenue of $0.00 EQUITY | Nov 05, 2026, 01:22 PM UTC M SCYNEXIS Reports Zero Revenue and $0.71 Loss Per Share in Q3 2026 SCYNEXIS reported no license agreement revenue in the quarter, compared with $334,000 a year earlier, while its net loss narrowed slightly. Lower R&D costs tied to the terminated MARIO Phase 3 study and higher interest a EARNINGS | Nov 05, 2026, 01:21 PM UTC L Scynexis Secures Up to $214 Million BARDA Cost-Share Award to Advance SCY-247 Scynexis entered into a cost-share BARDA Contract to fund development of SCY-247, a second-generation fungerp antifungal. The award provides up to $214 million in non-dilutive support, including an $18.5 million base per NEWS | Sep 28, 2026, 08:06 PM UTC L SCYNEXIS, Inc. (SCYX) Wins BARDA Contract Worth Up To $214M SCYNEXIS was awarded a BARDA contract providing up to $214M if all options are exercised to develop SCY-247 through potential NDA submissions. The base period provides ~$18.5M to advance oral and IV SCY-247 into a Phase NEWS | Sep 28, 2026, 11:32 AM UTC L SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. NASDAQ:SCYX (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, NEWS | Sep 28, 2026, 11:32 AM UTC M SCYNEXIS awarded BARDA contract for SCY-247 development SCYNEXIS said BARDA awarded it a contract providing up to $214 million in non-dilutive funding for development of SCY-247. EQUITY | Sep 28, 2026, 11:30 AM UTC L SCYX - SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors SCYX - SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors NEWS | Sep 22, 2026, 12:00 PM UTC L SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. NASDAQ:SCYX (the Company or SCYNEXIS NEWS | Sep 15, 2026, 12:03 PM UTC L SCYX - SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development SCYX - SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development NEWS | Sep 15, 2026, 12:02 PM UTC L SCYNEXIS appoints Sanjay Subramanian as CFO EQUITY | Sep 10, 2026, 12:41 PM UTC M SCYNEXIS names Sanjay Subramanian CFO as Ivor Macleod retires SCYNEXIS appointed Sanjay Subramanian as chief financial officer effective September 9, 2026. Ivor Macleod retired from the CFO role effective the same date and will remain through October 9, 2026 to support the transiti EQUITY | Sep 10, 2026, 12:14 PM UTC L Scynexis Macleod to remain through Oct 9 EQUITY | Sep 10, 2026, 12:04 PM UTC L Scynexis CFO Ivor Macleod retires effective Sept. 9 EQUITY | Sep 10, 2026, 12:04 PM UTC L Scynexis Subramanian appointment effective Sept. 9 EQUITY | Sep 10, 2026, 12:03 PM UTC L SCYNEXIS appoints Sanjay Subramanian as chief financial officer EQUITY | Sep 10, 2026, 12:03 PM UTC L SCYNEXIS appoints Sanjay Subramanian as CFO EQUITY | Sep 10, 2026, 12:01 PM UTC L SCYNEXIS to participate in upcoming investor conferences SCYNEXIS, Inc. says it will participate in upcoming investor conferences, according to a company announcement. EQUITY | Sep 01, 2026, 12:37 PM UTC L SCYX - SCYNEXIS to Participate in Upcoming Investor Conferences SCYX - SCYNEXIS to Participate in Upcoming Investor Conferences EQUITY | Sep 01, 2026, 12:31 PM UTC H SCYX Surges 27% SCYX rises 27% EQUITY | Jul 31, 2026, 07:00 PM UTC H Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pedi Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance REGULATION | Jul 31, 2026, 04:04 PM UTC H SCYX resumes trading, now +8% SCYX trading resumes with 8% gain EQUITY | Jul 31, 2026, 04:03 PM UTC H SCYX Halted on Downside Volatility SCYX trading halted due to volatility EQUITY | Jul 31, 2026, 03:58 PM UTC L SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens SCYNEXIS, Inc. (NASDAQ: SCYX ), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP EQUITY | Jun 30, 2026, 12:02 PM UTC